DPP4 and metabolic dysfunction-associated steatotic liver disease: Studies in mice using several tissue-specific targeting strategies have confirmed that the elevation of circulating DPP4 in obesity is liver derived (22–24), suggesting that DPP4 produced in the liver may primarily contribute to the progression of NAFLD (25).